Switch theme
Sign up to access all valuation multiples
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
2003
17
LTM Revenue $18.1M
LTM EBITDA $13.9M
$197M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bioventix has a last 12-month revenue (LTM) of $18.1M and a last 12-month EBITDA of $13.9M.
In the most recent fiscal year, Bioventix achieved revenue of $18.3M and an EBITDA of $14.4M.
Bioventix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bioventix valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $18.1M | XXX | $18.3M | XXX | XXX | XXX |
| Gross Profit | $16.4M | XXX | $17.0M | XXX | XXX | XXX |
| Gross Margin | 91% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | $13.9M | XXX | $14.4M | XXX | XXX | XXX |
| EBITDA Margin | 77% | XXX | 79% | XXX | XXX | XXX |
| EBIT | $13.6M | XXX | $14.3M | XXX | XXX | XXX |
| EBIT Margin | 75% | XXX | 78% | XXX | XXX | XXX |
| Net Profit | $10.8M | XXX | $10.9M | XXX | XXX | XXX |
| Net Margin | 59% | XXX | 60% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bioventix's stock price is GBP 29 (or $39).
Bioventix has current market cap of GBP 152M (or $203M), and EV of GBP 146M (or $197M).
See Bioventix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $197M | $203M | XXX | XXX | XXX | XXX | $2.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bioventix has market cap of $203M and EV of $197M.
Bioventix's trades at 10.8x EV/Revenue multiple, and 13.9x EV/EBITDA.
Equity research analysts estimate Bioventix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bioventix has a P/E ratio of 18.9x.
See valuation multiples for Bioventix and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $203M | XXX | $203M | XXX | XXX | XXX |
| EV (current) | $197M | XXX | $197M | XXX | XXX | XXX |
| EV/Revenue | 10.8x | XXX | 10.8x | XXX | XXX | XXX |
| EV/EBITDA | 14.2x | XXX | 13.9x | XXX | XXX | XXX |
| EV/EBIT | 14.4x | XXX | 14.1x | XXX | XXX | XXX |
| EV/Gross Profit | 12.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.9x | XXX | 18.8x | XXX | XXX | XXX |
| EV/FCF | 20.1x | XXX | 18.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioventix's last 12 month revenue growth is 0%
Bioventix's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.2M for the same period.
Bioventix's rule of 40 is 79% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bioventix's rule of X is 76% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bioventix and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | 77% | XXX | 78% | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 79% | XXX | 78% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 76% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bioventix acquired XXX companies to date.
Last acquisition by Bioventix was XXXXXXXX, XXXXX XXXXX XXXXXX . Bioventix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bioventix founded? | Bioventix was founded in 2003. |
| Where is Bioventix headquartered? | Bioventix is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Bioventix have? | As of today, Bioventix has 17 employees. |
| Who is the CEO of Bioventix? | Bioventix's CEO is Mr. Peter John Harrison. |
| Is Bioventix publicy listed? | Yes, Bioventix is a public company listed on LON. |
| What is the stock symbol of Bioventix? | Bioventix trades under BVXP ticker. |
| When did Bioventix go public? | Bioventix went public in 2014. |
| Who are competitors of Bioventix? | Similar companies to Bioventix include e.g. Zomedica, AnteoTech, Proteomics International, Biohit. |
| What is the current market cap of Bioventix? | Bioventix's current market cap is $203M |
| What is the current revenue of Bioventix? | Bioventix's last 12 months revenue is $18.1M. |
| What is the current revenue growth of Bioventix? | Bioventix revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Bioventix? | Current revenue multiple of Bioventix is 10.8x. |
| Is Bioventix profitable? | Yes, Bioventix is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bioventix? | Bioventix's last 12 months EBITDA is $13.9M. |
| What is Bioventix's EBITDA margin? | Bioventix's last 12 months EBITDA margin is 77%. |
| What is the current EV/EBITDA multiple of Bioventix? | Current EBITDA multiple of Bioventix is 14.2x. |
| What is the current FCF of Bioventix? | Bioventix's last 12 months FCF is $9.8M. |
| What is Bioventix's FCF margin? | Bioventix's last 12 months FCF margin is 54%. |
| What is the current EV/FCF multiple of Bioventix? | Current FCF multiple of Bioventix is 20.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
